# Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.

> **NCT04730895** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kafrelsheikh University** · enrollment: 360 (estimated)

## Conditions studied

- Covid19 Vaccine

## Interventions

- **DRUG:** Oral 13 cis retinoic acid
- **DRUG:** Aerosolized 13 cis retinoic acid
- **COMBINATION_PRODUCT:** 13 cis retinoic acid doses orally in combination with spike protein based vaccine
- **COMBINATION_PRODUCT:** Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine
- **BIOLOGICAL:** Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine

## Key facts

- **NCT ID:** NCT04730895
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2021-09
- **Final completion:** 2023-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730895, "Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04730895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*